Is Augmentin (amoxicillin-clavulanate) effective in treating pneumonia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does Augmentin Treat Pneumonia?

Yes, Augmentin (amoxicillin-clavulanate) is an effective and guideline-recommended treatment for community-acquired pneumonia, particularly when beta-lactamase-producing organisms or penicillin-resistant Streptococcus pneumoniae are suspected. 1

FDA-Approved Indication

Augmentin is FDA-approved specifically for lower respiratory tract infections caused by beta-lactamase-producing isolates of Haemophilus influenzae and Moraxella catarrhalis. 1 The drug combines amoxicillin with clavulanate, a beta-lactamase inhibitor that protects amoxicillin from enzymatic degradation and extends coverage to organisms that would otherwise be resistant. 1

Guideline-Based Recommendations

Adults with Community-Acquired Pneumonia

  • For empiric treatment of bacterial superinfection following influenza, amoxicillin-clavulanate is explicitly recommended to provide activity against S. pneumoniae, Staphylococcus aureus, and H. influenzae. 2

  • For adults with risk factors (such as recent antibiotic use, comorbidities, or concern for resistant pathogens), amoxicillin-clavulanate provides broader spectrum coverage than amoxicillin alone, addressing beta-lactamase-producing H. influenzae and penicillin-resistant S. pneumoniae. 2

  • The standard adult dosing is 875 mg/125 mg every 12 hours or 500 mg/125 mg every 8 hours for 7-10 days. 3

Children with Pneumonia

  • For children under 3 years with non-severe pneumonia, high-dose amoxicillin-clavulanate (80-90 mg/kg/day of amoxicillin component with maximum 6.4 mg/kg/day clavulanic acid in divided doses) is recommended as a second-line agent when first-line amoxicillin fails or when enhanced coverage against beta-lactamase-producing H. influenzae and resistant S. pneumoniae is needed. 2

  • For children 3-5 years, amoxicillin-clavulanate at 80 mg/kg/day is justified when there is insufficient vaccination against H. influenzae type b or coexisting purulent acute otitis media. 3

Clinical Efficacy Evidence

  • Over 20 years of clinical use demonstrates that amoxicillin-clavulanate maintains high bacteriological and clinical efficacy in respiratory tract infections despite increasing antimicrobial resistance. 4

  • Clinical trials in community-acquired pneumonia show excellent bacteriological and clinical success rates, even against antimicrobial-resistant pathogens including S. pneumoniae with reduced penicillin susceptibility (MIC ≤2.0 mcg/mL). 5

  • A pharmacokinetically enhanced formulation (Augmentin XR: 2000/125 mg twice daily) has been developed specifically for adult respiratory infections due to drug-resistant pathogens, demonstrating efficacy against H. influenzae strains with MICs up to 4/2 mg/L. 6, 7

When Augmentin Should NOT Be Used

  • When susceptibility testing shows the organism is susceptible to amoxicillin alone (indicating no beta-lactamase production), plain amoxicillin should be used instead of amoxicillin-clavulanate to avoid unnecessary clavulanate exposure. 1

  • For atypical pneumonia caused by Mycoplasma pneumoniae or Chlamydophila pneumoniae, amoxicillin-clavulanate lacks activity and a macrolide or respiratory fluoroquinolone should be used instead. 2

Monitoring and Treatment Failure

  • Assess therapeutic efficacy within 2-3 days of initiating treatment. 3 Fever should resolve within 24 hours for pneumococcal infections and 2-4 days for other bacterial etiologies. 8

  • If no improvement occurs within 72 hours, do not change antibiotics immediately unless the patient's clinical state worsens. 2 Consider clinical and radiological reassessment, and hospitalization may be necessary for complications such as empyema. 2, 3

  • Cough may persist longer than other symptoms and should not be used as the sole indicator of treatment failure. 8

Common Pitfalls to Avoid

  • Do not assume all beta-lactams are equivalent—first-generation cephalosporins like cephalexin lack adequate activity against respiratory pathogens and should never be substituted for amoxicillin-clavulanate in pneumonia. 8

  • In patients with immediate Type I hypersensitivity reactions to beta-lactams, alternative non-beta-lactam antibiotics carry bacterial failure rates of 20-25%, so careful consideration is needed. 3

  • Augmentin can be given without regard to meals for amoxicillin absorption, though clavulanate absorption is enhanced when taken with food. 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.